AstraZeneca Aktie
| 63,75USD | 0,56USD | 0,88% |
WKN: 886715 / ISIN: US0463531089
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,97 |
| PRIMECAP Management Co. | 1,35 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 1,19 |
| Capital Research & Management Co. (International Investors) | 1,19 |
| Wellington Management Co. LLP (Wellington Breakout) | 1,15 |
| T. Rowe Price International Ltd. | 0,84 |
| Vanguard PRIMECAP Fund | 0,83 |
| Washington Mutual Investors Fund | 0,76 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 70 600 | 76 100 | 83 100 | 83 500 | 89 900 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,35 | 0,36 | 0,46 | 0,53 | 0,51 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 15 563 | 19 544 | 26 244 | 22 593 | 25 054 |
| Summe Anlagevermögen | 45 814 | 47 185 | 79 119 | 73 890 | 76 065 |
| Summe Aktiva | 61 377 | 66 729 | 105 363 | 96 483 | 101 119 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 18 227 | 20 380 | 30 781 | 29 232 | 28 622 |
| Summe Fremdkapital | 46 781 | 51 091 | 66 076 | 59 425 | 61 953 |
| Summe Eigenkapital | 14 596 | 15 638 | 39 287 | 37 058 | 39 166 |
| Summe Passiva | 61 377 | 66 729 | 105 363 | 96 483 | 101 119 |
Adresse
| Cambridge Biomedical Campus, CB2 0AA Cambridge | |
| Telefon | +44 (20) 3749-5000 |
| Internet | http://www.astrazeneca.co.uk |
Management
|
Adrian Charles Noel Kemp
Secretary |
|
Alberto Hegewisch
Chief Medical Officer |
|
Andreas Rummelt
Non-Executive Director |
|
Anna Olive Magdelene Manz
Non-Executive Director |
|
Aradhana Sarin
Chief Financial Officer & Executive Director |
|
Cindy L. Hoots
Chief Digital & Information Officer |
|
David Fredrickson
Executive Vice President-Oncology Business Unit |
|
Deborah DiSanzo
Independent Non-Executive Director |
|
Diana Layfield
Non-Executive Director |
|
Euan A. Ashley
Non-Executive Director |
|
Helen MacPhee
Vice President |
|
Iskra Reic
EVP-Vaccines & Immune Therapies |
|
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel |
|
Jonathan Thomas Charles Slade
Group Treasurer |
|
Kevin G. Lokay
Head-Change Implementation |
|
Marc Pierre Jean Dunoyer
Chief Strategy Officer |
|
Marcus Wallenberg
Independent Non-Executive Director |
|
Margareta Elisabeth Björk
Senior VP & Head-Late-stage Development |
|
Michel Demaré
Chairman |
|
Nazneen Rahman
Independent Non-Executive Director |
|
Pam P. Cheng
Executive VP-Operations & Information Technology |
|
Pascal Soriot
Chief Executive Officer & Executive Director |
|
Philip Arthur John Broadley
Senior Independent Non-Executive Director |
|
Regina Fritsche-Danielson
SVP, Head-Research & Early Development |
|
Ruud Dobber
Executive VP-Biopharmaceuticals Business |
|
Sharon Barr
EVP-BioPharmaceuticals Research & Development |
|
Sherilyn D. McCoy
Independent Non-Executive Director |
|
Shu Kam Mok
Independent Non-Executive Director |
|
Sjoerd Hubben
Vice President-Global Government Affairs & Policy |
|
Susan Mary Galbraith
Executive VP-Oncology Research & Development |
|
Tyrell J. Rivers
Executive Director-Corporate Development |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
